* Gets approval for laser device to treat pigmentation
* Shares up 31 pct in after-hours trade
Oct 14 (Reuters) - Aesthetic laser device maker Solta Medical Inc said it received U.S. regulatory approval for its device to clear pigmentation and other superficial skin conditions, sending its shares up 31 percent.
The company said the device, called the Fraxel re:store Dual Laser System, can be used both on the face and large body areas to address clearance of pigmentation in a single treatment.
The company already has regulatory approval for the device with a 1550 nanometer (nm) wavelength for skin resurfacing and treatment of pigmented lesions and certain other skin conditions.
The new approval is for the Fraxel 1927 nm laser for dermatological procedures requiring the coagulation of soft tissue.
Shares of the company were up 31 percent to $2.89 in trading after the bell. They closed at $2.19 Wednesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Aradhana Aravindan) Keywords: SOLTAMEDICAL/ (krishnakali.sengupta@thomsonreuters.com; within U.S +1 646 223 8780; outside U.S +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Shares up 31 pct in after-hours trade
Oct 14 (Reuters) - Aesthetic laser device maker Solta Medical Inc said it received U.S. regulatory approval for its device to clear pigmentation and other superficial skin conditions, sending its shares up 31 percent.
The company said the device, called the Fraxel re:store Dual Laser System, can be used both on the face and large body areas to address clearance of pigmentation in a single treatment.
The company already has regulatory approval for the device with a 1550 nanometer (nm) wavelength for skin resurfacing and treatment of pigmented lesions and certain other skin conditions.
The new approval is for the Fraxel 1927 nm laser for dermatological procedures requiring the coagulation of soft tissue.
Shares of the company were up 31 percent to $2.89 in trading after the bell. They closed at $2.19 Wednesday on Nasdaq.
(Reporting by Krishnakali Sengupta in Bangalore; Editing by Aradhana Aravindan) Keywords: SOLTAMEDICAL/ (krishnakali.sengupta@thomsonreuters.com; within U.S +1 646 223 8780; outside U.S +91 80 4135 5800; Reuters Messaging: krishnakali.sengupta.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
